Literature DB >> 21179594

The role of pramipexole in a severe Parkinson's disease model in mice.

Seham Gad Elhak1, Abdel Aziz Ghanem, Hasan Abdelghaffar, Sahar Eldakroury, Dina Eltantawy, Sara Eldosouky, Mohamed Salama.   

Abstract

BACKGROUND: Pramipexole is one of a new generation of dopamine agonists. Recently there have been questions regarding its neuroprotective effects. These effects have been tested against various insults, which have yielded conflicting results.
METHODS: In this study, we introduced a combination of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/paraquat to induce a severe Parkinson's disease model. The mice, after receiving the combination of toxins, were evaluated using mortality rates and immunohistochemistry for degenerating tyrosine hydroxylase-positive neurons. RESULTS AND
CONCLUSIONS: Pramipexole was tested for its capacity to offer protection against neurotoxic the effects of MPTP/paraquat in this model; however, the results showed no improvement with pramipexole therapy.

Entities:  

Keywords:  MPTP; Parkinson’s disease; mouse; neuroprotection; paraquat; pramipexole

Year:  2010        PMID: 21179594      PMCID: PMC3002641          DOI: 10.1177/1756285610389655

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  17 in total

Review 1.  Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's disease.

Authors:  S S Riaz; H F Bradford
Journal:  Prog Neurobiol       Date:  2005-10-26       Impact factor: 11.685

2.  Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in mice.

Authors:  Franziska Richter; Melanie Hamann; Angelika Richter
Journal:  Brain Res       Date:  2007-10-12       Impact factor: 3.252

3.  On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea).

Authors:  Peter S Spencer; Valerie S Palmer; Albert C Ludolph
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

4.  Neuroprotection in Parkinson models varies with toxin administration protocol.

Authors:  David W Anderson; Kristin A Bradbury; Jay S Schneider
Journal:  Eur J Neurosci       Date:  2006-12       Impact factor: 3.386

Review 5.  Neuronal cell replacement in Parkinson's disease.

Authors:  E Hedlund; T Perlmann
Journal:  J Intern Med       Date:  2009-10       Impact factor: 8.989

6.  A highly reproducible rotenone model of Parkinson's disease.

Authors:  Jason R Cannon; Victor Tapias; Hye Mee Na; Anthony S Honick; Robert E Drolet; J Timothy Greenamyre
Journal:  Neurobiol Dis       Date:  2009-05       Impact factor: 5.996

Review 7.  Disease model: Parkinson's disease.

Authors:  Shun Shimohama; Hideyuki Sawada; Yoshihisa Kitamura; Takashi Taniguchi
Journal:  Trends Mol Med       Date:  2003-08       Impact factor: 11.951

8.  Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexole.

Authors:  Elyse S Kemmerer; Timothy J Desmond; Roger L Albin; Michael R Kilbourn; Kirk A Frey
Journal:  Exp Neurol       Date:  2003-09       Impact factor: 5.330

9.  The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat models.

Authors:  Mi Young Jeon; Won Yong Lee; Ho Young Kang; Eun Joo Chung
Journal:  Neurol Res       Date:  2007-04       Impact factor: 2.448

Review 10.  Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?

Authors:  Emma Lane; Stephen Dunnett
Journal:  Psychopharmacology (Berl)       Date:  2007-09-25       Impact factor: 4.530

View more
  2 in total

Review 1.  The benefits of pramipexole selection in the treatment of Parkinson's disease.

Authors:  Mine Silindir; A Yekta Ozer
Journal:  Neurol Sci       Date:  2014-07-20       Impact factor: 3.307

2.  Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.

Authors:  Vicente Lieberknecht; Stella C Junqueira; Mauricio P Cunha; Thaís A Barbosa; Luiz F de Souza; Igor S Coelho; Adair R S Santos; Ana Lúcia S Rodrigues; Alcir L Dafré; Rafael C Dutra
Journal:  Mol Neurobiol       Date:  2016-01-22       Impact factor: 5.590

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.